Getinge completes acquisition of FLUOPTICS SAS

Getinge has today completed the previously announced acquisition of 100% of the shares in FLUOPTICS SAS.

On April 27, 2022, Getinge announced an agreement to acquire FLUOPTICS SAS, a French based leader in fluorescence imaging as an aid to surgery.

All conditions for the transaction and closing have now been fulfilled. The transaction was completed today with effect as from July 1, 2022. Getinge has paid approximately 23 mEUR in cash on closing for 100 % of the shares on a cash and debt free basis , which is subject to further post closing adjustments. Moreover, additional earn-out may be paid if agreed milestones are achieved. The acquisition was financed through available cash. Getinge expects no material integration costs.

The acquisition will expand Getinge’s customer offering in clinical decision support by providing safe and improved operating efficiency. The addressable global market is estimated to be more than SEK 2.5 B, recording an annual compounded average growth rate of 8 % during the forecasted period (2020-2025). More than 380 institutions in US, Europe and Asia are currently using the FLUOPTICS technology in their daily clinical routine with over 40,000 procedures performed.

For more information about FLUOPTICS SAS: https://fluoptics.com/en/

To read the press release from April 27, 2022, click here or visit www.getinge.com.

Media contact:

Lars Mattson, Head of Investor Relations
Tel: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com

About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.